Please ensure Javascript is enabled for purposes of website accessibility

These 4 Dow Stocks Can Double Your Money in 7 Years (or Less)

By Sean Williams – Sep 13, 2021 at 6:06AM

Key Points

  • The Dow Jones Industrial Average is a widely-followed barometer of the stock market's health.
  • These time-tested companies could deliver big-time returns for investors in the years to come.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Of the Dow's 30 components, these four could be its biggest winners.

For more than 125 years, the iconic Dow Jones Industrial Average (^DJI 2.18%) has served as a barometer for the health of the U.S. stock market. Comprised of 30 profitable and time-tested companies, the Dow Jones is the perfect example of how buy-and-hold investing can make investors rich.

Over the trailing 50 years, the Dow has averaged an annualized return of about 7.5%. On a compounded basis, this means the Dow Jones Industrial Average is doubling roughly every 10 years.

But investors may not have to wait a full decade to see their initial investment double in value. The following four Dow stocks all have the potential to double investors' money over the next seven years, or perhaps even sooner.

A person using a stylus to interact with a rapidly rising chart on a tablet screen.

Image source: Getty Images.


Of the Dow's 30 components, the one I believe offers the best chance to double investors' money in seven years or less is cloud-based customer relationship management (CRM) software provider (CRM 5.65%). For those wondering, CRM software is used by consumer-facing businesses to enhance client relationships and boost sales.

The reason Salesforce is such a no-brainer outperformer has to do with its dominant market share in global CRM. When IDC analyzed global CRM spending in the first half of 2020, it found that Salesforce gobbled up just shy of 20% of all sales. That's more than its four closest competitors, combined. It's the clear go-to platform for CRM, which is a sustainable double-digit growth opportunity as businesses digitize their operations.

Salesforce has also done an excellent job of making earnings-accretive acquisitions. CEO Marc Benioff has overseen the buyouts of MuleSoft, Tableau, and most recently Slack Technologies. Buying cloud-based enterprise communications platform Slack gives Salesforce another jumping-off point with which to cross-sell its products and services, while exposing the company to a broader swath of small and medium-sized businesses.

If Benioff's projection is accurate, Salesforce will more than double its sales in five years to $50 billion.

A doctor speaking with a patient in an exam room.

Image source: Getty Images.

UnitedHealth Group

The great thing about healthcare stocks is that they're highly defensive. No matter how well or poorly the U.S. economy is performing, demand for drugs, devices, and healthcare services remains relatively steady. That's why UnitedHealth Group (UNH 3.74%) is a good bet to double investors' money over the next seven years.

Most folks are probably familiar with UnitedHealth's insurance operations. Health insurance isn't necessarily a fast-growing segment, but it does provide strong premium pricing power and the ability to grow profitability by a mid-single-digit percentage over time. If Democrats were to remain in control of Congress for years to come, an expansion of healthcare coverage could be a boon to UnitedHealth.

However, the big-time long-term growth driver for UnitedHealth is its subsidiary Optum, which is a pharmacy-benefits manager and healthcare services company. Optum handles everything from pharmacy care services to data analytics for hospitals and healthcare organizations. Optum's sales are growing considerably faster than UnitedHealth's insurance segment, and its operating margins should be superior.

With sustainable sales growth of around 10% and a growing dividend, UnitedHealth Group could be just what the doctor ordered.

A smiling pharmacist holding a prescription bottle speaking with a customer.

Image source: Getty Images.

Walgreens Boots Alliance

Another healthcare stock with all the tools needed to double investors' money by 2028 or earlier is pharmacy chain Walgreens Boots Alliance (WBA 1.02%). Even though Walgreens and its pharmacy peers were clobbered by reduced foot traffic during the pandemic, the company's multipoint turnaround plan should have its business humming along in no time.

According to management, Walgreens is ahead of schedule on the cost-saving front. The company expects to have reduced its annual operating expenses by at least $2 billion in fiscal 2022. All the while, significant investments are being made in Walgreens' digitization initiatives, which were accelerated during the pandemic. Although direct-to-consumer sales still take a back seat to in-store purchases, online sales should be a sustainable rapid growth opportunity for the company.

Arguably the most exciting aspect of Walgreens' turnaround strategy is its partnership with VillageMD. This duo plans to open as many as 700 full-service clinics co-located in Walgreens' stores in more than 30 U.S. markets. Since most in-store clinics can only handle very simple tasks, such as vaccines, this initiative could be the key to drawing in repeat customers and funneling them to Walgreens' high-margin pharmacy.

At 10 times forward-year earnings per share, Walgreens Boots Alliance is currently one of the cheapest Dow stocks.

Smiling person holding up a credit card.

Image source: Getty Images.


Last but not least, payment processing giant Visa (V 3.80%) can charge higher over the next seven years and double your money.

The beauty of the Visa operating model is that it's cyclical. Despite recessions being a normal part of the economic cycle, they often only last a few months or a couple of quarters. By comparison, periods of economic expansion typically go on for years, or even a decade. Visa is able to roll with the punches for a few quarters during a recession, but benefits immensely from disproportionately long periods of economic growth.

Visa is also the most dominant player in the No. 1 market for consumption in the world: The United States. In 2018, it held a 53% share of credit card network purchase volume in the U.S., which was more than 30 percentage points higher than its next-closest competitor.

It happens to have a long runway for infrastructure expansion, too. Since most global transactions are still being conducted in cash, Visa has the opportunity to expand its infrastructure organically or through acquisition into emerging markets. This should allow Visa to maintain a growth rate near 10%, as well as a profit margin at or above 50%.

Sean Williams owns shares of Walgreens Boots Alliance. The Motley Fool owns shares of and recommends and Visa. The Motley Fool recommends UnitedHealth Group. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Nearly 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Visa Stock Quote
$217.00 (3.80%) $7.94
Dow Jones Industrial Average (Price Return) Stock Quote
Dow Jones Industrial Average (Price Return)
$34,589.77 (2.18%) $737.24
Salesforce Stock Quote
$160.25 (5.65%) $8.57
Walgreens Boots Alliance Stock Quote
Walgreens Boots Alliance
$41.50 (1.02%) $0.42
UnitedHealth Group Stock Quote
UnitedHealth Group
$547.76 (3.74%) $19.76

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.